Background. There is little known about the dynamics of the infant virome and how it relates to healthy growth and development. This study will establish the baseline gut virome and observe dynamic changes in a cohort of infants from birth to 3 years old. We hypothesize that changes in the gut virome will impact growth and immune development.
Methods. One hundred and twenty-eight infants were enrolled in the Stanford's Outcome Research in Kids (STORK) cohort prior to 36 weeks gestation. Stool samples were collected at an average of 90, 134, 162 days old/infant. Baseline data were collected at birth (height, weight, length, Apgar's score, antibiotic use) and health surveys were collected weekly. Stool samples (n = 477) were extracted using the EZ1 Viral Kit (Qiagen). Libraries were prepared using the Nextera XT kit (Illumina) and sequenced on an Illumina HiSeq 2500 on rapid mode (150/150 bp paired-end sequencing). Datasets were analyzed using SURPI; a bioinformatic pipeline for pathogen detection.
Results. A subset of the infants were tested (n = 27), 54% of which were male. The infants were 62% white, Hispanic, 26% white, non-Hispanic, 8% Asian, and 4% other. Seventy-five stool samples-sequenced at an average depth of 22 million reads-were analyzed from the 27 infants. Vertebrate viruses (42.8%) and phages (45.2%) represented the majority of the viral reads, while the other reads were invertebrate, plants or protozoa (12%). Virome abundance, richness, and diversity were 5.5e+04 species reads per million, 55.5 on the Chao Richness scale, and 1.45 on the Shannon Diversity Index respectively, with values increasing as the infants aged. The phage families most commonly identified were Myoviridae, Podoviridae, and Siphoviridae. There were seven different human viral families observed: Adenoviridae, Astroviridae, Caliciviridae, Parvoviridae, Picornaviridae, Reoviridae, and Anelloviridae. Five infants were documented to have cold symptoms within 7 days of sampling, they were found to have mastadenovirus C (1), mamastrovirus 1 (1), bocavirus (3). Three infants were documented to have caliciviruses (2) and adenovirus (1); however, no symptoms were reported.
Conclusion. This study will comprehensively characterize the development of the human virome and monitor its effect on growth and immune development.
Disclosures. Methods. Patients undergoing FMT for rCDI via colonoscopy were enrolled. Clinical data and stool were collected pre-and 8 weeks post-FMT. Microbial profiles were assessed by 16S rRNA sequencing. Difference in microbial alpha and β-diversity between groups was determined. Significance testing was assessed using MannWhitney-Wilcoxon and PERMANOVA tests. The Jensen Shannon divergence (JSD) between donor and their recipient post-FMT was used as a measure of engraftment. The association of clinical factors on engraftment was evaluated by linear regression.
Results. A total of 12 patients received an FMT from 12 unique donors. The efficacy rate was 92%. Mean recipient age was 60 years (range: 33-87) with more females (7/12).
Recipients pre-FMT alpha diversity was significantly lower compare to donors (P = 0.04, Figure 1a) . This difference dissipated post-FMT (P = 0.67). On β-diversity analysis, the recipients pre-FMT samples clustered separately from their post-FMT samples (P = 0.01, Figure 1b) , with the post-FMT samples shifting closer to the donor samples. Proteobacteria was dominant in patients' pre-FMT samples and were substantially reduced post-FMT, combined with an expansion in Bacteroidetes (Figure 2) .
On linear regression analysis, clinical factors (age, sex, previous recurrent CDI episodes, inflammatory bowel disease, proton pump inhibitor, immunosuppression, previous anti-CDI antibiotic courses, probiotics) were not significantly associated with engraftment outcomes.
Conclusion. There is a significant and durable shift in recipients' microbial profile to resemble their donor post-FMT. Recipients' pre-FMT clinical factors did not significantly affect microbial engraftment. Future metagenomic studies may help elucidate whether clinical factors impact engraftment. 
